# India Glioblastoma Multiforme Market

> India Glioblastoma Multiforme Market Research Report: Size, Share, Trend Analysis By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field (TTF) Therapy, Others) and By End Users (Hospitals and Clinics, Ambulatory Surgical Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.52%
- **2024:** $ 147.05 Million
- **2025:** $ 159.58 Million
- **2035:** $ 361.54 Million
- **Key Players:** Bristol-Myers Squibb (US), Merck & Co (US), Roche (CH), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Pfizer (US), Bayer (DE)

**Report ID:** MRFR/HC/50495-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-glioblastoma-multiforme-market-52253

---

## Market Summary

## **India Glioblastoma Multiforme Market Overview**

As per MRFR analysis, the India Glioblastoma Multiforme Market Size was estimated at 108.37 (USD Million) in 2023. The India Glioblastoma Multiforme Market Industry is expected to grow from 117.6(USD Million) in 2024 to 470.4 (USD Million) by 2035. The India Glioblastoma Multiforme Market CAGR (growth rate) is expected to be around 13.431% during the forecast period (2025 - 2035).

## **Key****India Glioblastoma Multiforme Market****Trends Highlighted**

The India Glioblastoma Multiforme Market is characterized by significant trends that are influenced by a variety of key factors. An important factor contributing to the rise in the prevalence of brain tumors, such as glioblastoma, is the impact of environmental factors and lifestyle changes. The increased awareness of neurological disorders has encouraged a greater number of individuals to seek medical attention, resulting in earlier diagnosis and treatment. Additionally, the introduction of innovative therapies, including immunotherapy and targeted therapy, and advancements in medical technology are revolutionizing treatment approaches. 

Additionally, the Indian government is emphasizing the improvement of healthcare infrastructure and accessibility, which will facilitate the provision of improved treatment options for patients with glioblastoma. The Indian Glioblastoma Multiforme market offers the potential to develop personalized medication that is customized to the genetic profile of patients. There is potential for the development of innovative therapies that can enhance the quality of life and survival rates as research advances. Partnerships between universities, research institutions, and pharmaceutical companies can facilitate innovation in drug development and treatment methodologies. 

In recent years, there has been an increasing trend of clinical trials being conducted in India, which is fostering local involvement in global research endeavors. Furthermore, the utilization of digital health technologies, including telemedicine, is increasing, enabling patients in remote regions to obtain expert opinions and treatments without geographical limitations.These factors contribute to a more robust Glioblastoma Multiforme market landscape in India, indicating a vibrant path forward for both patient care and research initiatives.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

## **India Glioblastoma Multiforme Market Drivers**

Increasing Prevalence of Glioblastoma Multiforme Cases

The rising number of glioblastoma multiforme cases in India is a significant driver for the India Glioblastoma Multiforme Market Industry. Current statistics indicate that the incidence of brain tumors, particularly glioblastoma, has been increasing, with a reported rise of approximately 4.4 percent annually according to the Indian Council of Medical Research (ICMR). The ICMR has highlighted that brain tumors account for approximately 2 percent of all cancers in India, and the number of new cases is expected to exceed 20,000 every year.

Such alarming trends necessitate growing investments in both treatment options and advanced technologies. Major pharmaceutical organizations, such as Cipla and Sun Pharmaceutical Industries, are actively engaged in Research and Development (R&D) of novel therapeutic agents and delivery systems tailored to address the unique challenges posed by glioblastoma. This continuous research is fostering an environment conducive to market growth, as more effective therapies become available to combat this aggressive form of cancer.

Advancements in Medical Technology and Treatment Approaches

Rapid advancements in medical technology, including innovative surgical techniques and targeted therapies, are propelling the India Glioblastoma Multiforme Market Industry forward. Techniques such as awake craniotomy and laser interstitial thermal therapy (LITT) have shown promise in improving patient outcomes. According to the Ministry of Health and Family Welfare, the adoption of these advanced methodologies has been on the rise, leading to better surgical precision and enhanced survival rates.

Additionally, companies like Dr. Reddy's Laboratories are innovating with novel chemotherapy alongside precision medicine strategies, which aim to tailor treatments to the genetic profiles of glioblastoma patients. This level of customization in treatment regimens caters to the specific needs of individuals, thereby improving the quality of healthcare in India and contributing to the growth of the market.

Government Initiatives and Support for Cancer Treatment

The Indian government has been increasingly supportive of cancer research, which directly influences the India Glioblastoma Multiforme Market Industry. Initiatives such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) have led to improved awareness and increased resources allocated for cancer treatment and research. The government's push for public-private partnerships in health infrastructure enhances access to novel treatment options.

A 2020 report from the Ministry of Health estimated that cancer-related healthcare infrastructure investments would reach approximately INR 25 billion over five years. This investment supports advanced therapies and paves the way for more companies, such as Zydus Cadila, to introduce innovative treatment solutions, ultimately benefiting glioblastoma patients in India.

## **India Glioblastoma Multiforme Market Segment Insights**

### **Glioblastoma Multiforme Market Treatment Type Insights**

The Treatment Type segment of the India Glioblastoma Multiforme Market represents a crucial aspect of the overall management and care of patients suffering from this aggressive form of brain cancer. The approach to treatment is often multi-faceted, incorporating various methodologies to combat the disease and enhance patient outcomes. Surgery, as a primary intervention, plays a pivotal role in the initial management of glioblastoma, with the aim of reducing tumor mass and potentially improving prognosis. It typically involves resecting as much of the tumor as possible, and is often complemented by additional treatment modalities to ensure comprehensive care.

Radiation Therapy remains an integral component in the overall treatment framework, as it is utilized post-surgery to target residual cancer cells, thereby minimizing the risk of recurrence. This method employs high-energy waves to obliterate cancerous cells and is widely adopted due to its effectiveness in enhancing patient survival rates.Chemotherapy contributes significantly to the treatment landscape, offering a systemic approach designed to target cancer cells throughout the body. Typically administered through various regimens, its role in conjunction with surgery and radiation is to tackle cells that may not have been removed in surgical procedures.

Furthermore, advancing therapies in Immunotherapy are emerging, leveraging the body’s immune system to recognize and fight glioblastoma cells, thus showcasing a new frontier in the treatment paradigm.

Tumor Treating Field (TTF) Therapy, although more novel, is gaining traction for its non-invasive method that utilizes electric fields to disrupt the division of cancer cells. This technique underscores the trend towards integrating technology in treatment protocols and illustrates the industry's direction towards innovative solutions.

Additionally, other treatments may encompass novel drug therapies and targeted treatments, illustrating the dynamic nature of the India Glioblastoma Multiforme Market.Overall, these treatment types are characterized by their interdependence and complementary roles in managing glioblastoma, reflecting the significant market trends driven by advancements in medical technology, an increasing focus on individualized treatment approaches, and ongoing Research and Development efforts. 

Challenges remain, particularly in terms of accessibility and affordability of advanced therapy options. Yet, the landscape is evolving to incorporate more effective strategies and resources for improving patient care in India. The collective impact of these treatment modalities underlines the commitment within the healthcare sector to enhance outcomes for patients battling glioblastoma multiforme, making significant strides in what has historically been a daunting health challenge.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

### **Glioblastoma Multiforme Market End User Insights**

The end-user segment of the India Glioblastoma Multiforme Market is characterized by a diverse range of healthcare settings, including Hospitals and Clinics, Ambulatory Surgical Centers, and Others. Hospitals and Clinics typically play a pivotal role in the diagnosis and treatment of glioblastoma multiforme due to their extensive resources and specialized medical professionals, thereby serving as primary treatment hubs for patients. Ambulatory Surgical Centers have gained significance as they provide more cost-effective outpatient services for minor surgical interventions, aligning with the growing trend toward minimally invasive procedures in cancer care.

This segment is witnessing a shift as healthcare costs rise and patients seek more accessible treatment options. The Others category, which encompasses various healthcare facilities, also contributes to the market dynamics by catering to specific patient needs and providing supportive care services. Collectively, these settings significantly impact the India Glioblastoma Multiforme Market by influencing patient treatment pathways and overall healthcare outcomes, highlighting a robust engagement with innovative treatment modalities and advanced technologies in oncology.

This segment's importance is further reflected in the growing emphasis on improving patient experiences and outcomes within the Indian healthcare landscape.

**India Glioblastoma Multiforme Market Key Players and Competitive Insights:**

The India Glioblastoma Multiforme Market is a rapidly evolving segment within the healthcare industry, driven by an increasing prevalence of glioblastoma as one of the most aggressive forms of brain cancer. Companies in this market are focused on developing innovative treatment options, including targeted therapies and immunotherapies, to improve patient outcomes. The competitive landscape features several key players who leverage advancements in research and development, partnerships, and strategic collaborations to enhance their market presence.

As the healthcare infrastructure in India expands and research capabilities improve, the market is expected to attract more investment, fostering additional competition and ultimately benefiting patients through access to novel therapies.

AstraZeneca has established a notable presence in the India Glioblastoma Multiforme Market by focusing on innovative treatment solutions and patient-centric approaches. The company has a strong emphasis on research and development, with a dedicated pipeline geared towards neurological disorders, including glioblastoma. AstraZeneca benefits from its robust global infrastructure, which is complemented by its initiatives in India, allowing it to effectively navigate regulatory landscapes and provide tailored therapies to meet local health needs.

Their efforts in fostering educational and awareness campaigns about glioblastoma signify their commitment not only to treatment but also to patient support and community engagement, strengthening their market position further.

Roche has positioned itself as a significant player within the India Glioblastoma Multiforme Market through its comprehensive portfolio of oncology products and commitment to personalized medicine. The company’s key products targeting glioblastoma include groundbreaking therapies that leverage advanced genetic targeting capabilities. Roche's strengths are greatly enhanced by its clinical trial capabilities and collaborations with local research institutions, which allow for the swift translation of research into practice. Mergers and acquisitions have also played a role in strengthening Roche's offerings, providing access to innovative technologies and treatment methodologies. 

Additionally, Roche's sustained investment in India reflects its dedication to expanding its footprint and improving patient access to cutting-edge treatments, enabling the company to continue growing its influence in this competitive market landscape.

**Key Companies in the India Glioblastoma Multiforme Market Include:**

**India Glioblastoma Multiforme Market Industry Developments**

Recent developments in the India Glioblastoma Multiforme Market have been noteworthy, particularly regarding advancements in treatments and initiatives by key pharmaceutical companies. AstraZeneca and Roche continue to enhance their portfolios with innovative therapies aimed at tackling this aggressive form of brain cancer. In September 2023, Merck and Co. announced promising results from their latest clinical trials, potentially expanding their presence in the Indian market. Growth in the market valuation of companies like Amgen and Bayer is significantly impacting the landscape, reflecting an increasing focus on Research and Development for novel drugs.

Moreover, in July 2023, Celgene secured a strategic partnership with local firms to bolster its chemotherapy options, which indicates a growing trend towards collaboration in the Indian healthcare sector. The market is projected to see a compound annual growth rate of approximately 8% over the next few years, driven by rising incidence rates and advancements in medical technology.

Historical events, such as Bristol Myers Squibb's introduction of a new treatment regimen in March 2022, further illuminate the dynamics within the India Glioblastoma Multiforme Market, along with increasing government initiatives to improve cancer care and patient access to innovative therapies in the country.

## **India Glioblastoma Multiforme Market Segmentation Insights**

### **Glioblastoma Multiforme Market Treatment Type****Outlook**

### **Glioblastoma Multiforme Market End User****Outlook**

## Market Drivers

### Rising Incidence Rates

The glioblastoma multiforme market in India is experiencing growth due to the rising incidence rates of this aggressive brain tumor. Recent data indicates that the age-standardized incidence rate of glioblastoma in India is approximately 2.5 per 100,000 individuals. This increase in cases is likely to drive demand for innovative treatment options and diagnostic tools. As awareness of glioblastoma grows, healthcare providers are more inclined to invest in advanced therapies, thereby expanding the market. The increasing number of patients necessitates a robust healthcare infrastructure, which may lead to enhanced research and development initiatives within the glioblastoma multiforme market. Furthermore, the rising burden of this disease could prompt government and private sector collaborations to improve treatment accessibility and affordability, ultimately benefiting the overall market landscape.

### Growing Awareness and Education

Growing awareness and education regarding glioblastoma multiforme are pivotal drivers for the market in India. Increased public knowledge about the symptoms and risks associated with glioblastoma is likely to lead to earlier diagnosis and treatment. Campaigns by non-profit organizations and healthcare providers are instrumental in disseminating information about brain tumors, which may result in a higher number of patients seeking medical attention. This heightened awareness could translate into increased demand for diagnostic services and treatment options within the glioblastoma multiforme market. Additionally, educational programs targeting healthcare professionals are essential for improving diagnostic accuracy and treatment efficacy. As more practitioners become informed about the latest advancements in glioblastoma management, the overall quality of care is expected to improve, further stimulating market growth.

### Government Initiatives and Policies

Government initiatives and policies play a crucial role in shaping the glioblastoma multiforme market in India. The Indian government has been actively promoting cancer research and treatment through various programs aimed at improving healthcare access and affordability. For example, the National Cancer Control Program aims to reduce cancer incidence and mortality rates, which includes specific strategies for brain tumors like glioblastoma. Such initiatives are likely to enhance funding for research and development in the glioblastoma multiforme market, fostering innovation and collaboration among stakeholders. Furthermore, the establishment of cancer care centers across the country is expected to improve early diagnosis and treatment options, thereby positively impacting patient outcomes and market growth. These government efforts may also encourage private sector participation, leading to a more comprehensive approach to tackling glioblastoma in India.

### Investment in Research and Development

Investment in research and development is a critical driver for the glioblastoma multiforme market in India. The increasing focus on understanding the molecular mechanisms underlying glioblastoma is likely to lead to the discovery of novel therapeutic targets. Funding from both public and private sectors is essential for advancing clinical trials and developing innovative treatment strategies. Recent reports suggest that the Indian pharmaceutical industry is allocating a growing portion of its budget to oncology research, which includes glioblastoma. This trend indicates a commitment to addressing the unmet medical needs of patients suffering from this aggressive tumor. Furthermore, collaborations between academic institutions and biotech companies are expected to enhance the pace of research, potentially leading to breakthroughs in treatment options. As investment in R&D continues to rise, the glioblastoma multiforme market is poised for significant advancements.

### Technological Advancements in Treatment

Technological advancements in treatment modalities are significantly influencing the glioblastoma multiforme market in India. Innovations such as immunotherapy, gene therapy, and personalized medicine are emerging as promising avenues for addressing this challenging condition. For instance, the introduction of CAR T-cell therapy has shown potential in clinical trials, indicating a shift towards more targeted and effective treatment options. The market is likely to benefit from these advancements as they may lead to improved patient outcomes and survival rates. Additionally, the integration of artificial intelligence in treatment planning and monitoring could enhance the precision of therapies administered to glioblastoma patients. As these technologies become more prevalent, they are expected to attract investment and research funding, further propelling the growth of the glioblastoma multiforme market in India.

## Future Outlook

The [Glioblastoma Multiforme Market](https://www.marketresearchfuture.com/reports/glioblastoma-multiforme-market-12161) in India is projected to grow at an 8.52% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing patient awareness.

**New opportunities:**

- Development of targeted therapies for personalized treatment plans.
- Expansion of telemedicine services for remote patient monitoring.
- Investment in clinical trials for innovative drug formulations.

By 2035, the market is expected to exhibit robust growth and enhanced treatment options.

## Segment Insights

### By Treatment Type: Surgery (Largest) vs. Immunotherapy (Fastest-Growing)

The treatment type segment in the India glioblastoma multiforme market showcases significant variance in market share distribution among its constituents. Surgery currently represents the largest share, owing to its essential role in managing glioblastoma. Meanwhile, Radiation Therapy and Chemotherapy also maintain substantial shares, providing complementary support to surgical procedures. Immunotherapy, while smaller, is gaining traction due to advancements in treatment techniques, showing an increasing preference among oncologists and patients alike.

Growth trends within this segment are primarily driven by innovative treatment approaches and an increasing focus on personalized medicine. The rising adoption of Tumor Treating Fields (TTF) Therapy, alongside traditional methods, indicates a shift towards less invasive treatments that enhance patient quality of life. Moreover, ongoing clinical research and development are expected to foster further growth, particularly for emerging therapies like Immunotherapy, which promises improved outcomes for patients in the long term.

Surgery (Dominant) vs. Immunotherapy (Emerging)

Surgery is the dominant treatment modality in the segment, vital for initial tumor removal and improving overall survival rates. Surgeons employ various techniques, tailored to individual patient needs, which solidifies surgery's indispensable role. As techniques evolve, minimally invasive options are becoming more prevalent, drawing interest for their potential in reducing recovery times and complications. On the other hand, Immunotherapy is an emerging treatment that shows promise in targeting residual cancer cells post-surgery. With mechanisms that enhance the immune system's ability to recognize and destroy glioblastoma cells, Immunotherapy is gaining momentum. Its ability to adapt and respond to individual tumor characteristics marks a significant advancement in glioblastoma treatment options, aiming for improved efficacy and patient outcomes.

### By End User Type: Hospitals & Clinics (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

The market share distribution among the end user types in the India glioblastoma multiforme market shows that hospitals and clinics hold a significant portion, owing to their comprehensive treatment capabilities and access to advanced medical technologies. Ambulatory surgical centers are gaining traction, reflecting a shift towards more outpatient services, driven by the growing preference for less invasive procedures and the convenience they offer. 

Growth trends in this segment indicate a rising demand for specialized care in hospitals and clinics, facilitated by an increase in glioblastoma multiforme cases. Ambulatory surgical centers are expected to experience the fastest growth due to their operational efficiency and cost-effectiveness, appealing to patients seeking timely interventions without lengthy hospital stays. The focus on ambulatory care solutions aligns with the overall trends in the healthcare sector towards improved patient experiences.

Hospitals & Clinics (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals and clinics serve as the dominant end user type in the market due to their extensive resources, specialized staff, and ability to provide multidisciplinary treatment approaches for glioblastoma multiforme. These facilities are equipped with advanced technologies, enabling comprehensive care from diagnosis to treatment. In contrast, ambulatory surgical centers represent an emerging segment, emphasizing efficiency and outpatient care. They are increasingly favored for their ability to deliver surgical interventions in a less invasive manner, leading to quicker recovery times for patients. This shift reflects broader trends in healthcare, where accessibility and affordability are prioritized, positioning ambulatory centers as vital players in the evolving landscape of glioblastoma multiforme treatment.

## Competitive Benchmarking

The glioblastoma multiforme market is characterized by a dynamic competitive landscape, driven by a combination of innovative therapies, strategic partnerships, and regional expansions. Key players such as Bristol-Myers Squibb (US), Roche (CH), and Novartis (CH) are actively shaping the market through their focus on research and development, particularly in immunotherapy and targeted treatments. Bristol-Myers Squibb (US) has positioned itself as a leader in immuno-oncology, while Roche (CH) emphasizes personalized medicine, leveraging its extensive pipeline of therapies. Novartis (CH) is also notable for its commitment to advancing gene therapies, which collectively enhance the competitive environment by fostering a culture of innovation and collaboration among these major players.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with a mix of established pharmaceutical giants and emerging biotech firms. This fragmentation allows for diverse treatment options, yet the collective influence of key players like Merck & Co (US) and Eli Lilly and Company (US) is significant, as they drive market trends and set benchmarks for therapeutic advancements.
In October 2025, Merck & Co (US) announced a strategic collaboration with a leading Indian biotech firm to develop a novel combination therapy for glioblastoma multiforme. This partnership is expected to leverage local expertise and resources, potentially accelerating the development timeline and enhancing market access in India. Such collaborations may indicate a shift towards more localized approaches in drug development, which could be crucial for addressing specific patient needs in diverse populations.
In September 2025, Roche (CH) launched a new clinical trial for its innovative drug targeting glioblastoma multiforme, focusing on a unique biomarker-driven approach. This trial aims to evaluate the efficacy of the drug in a specific patient subset, which could redefine treatment protocols and enhance patient outcomes. The emphasis on biomarker identification suggests a growing trend towards precision medicine, aligning with Roche's strategic focus on personalized therapies.
In August 2025, Novartis (CH) expanded its research facilities in India, aiming to enhance its capabilities in developing advanced therapies for glioblastoma multiforme. This expansion reflects a commitment to investing in local infrastructure and talent, which may facilitate faster innovation cycles and improve the company's competitive positioning in the region. Such investments are likely to yield long-term benefits, as they align with the increasing demand for localized treatment solutions.
As of November 2025, current competitive trends indicate a strong focus on digitalization, sustainability, and the integration of artificial intelligence in drug development processes. Strategic alliances are becoming increasingly vital, as they enable companies to pool resources and expertise, thereby enhancing their competitive edge. The market appears to be shifting from price-based competition towards a landscape where innovation, technological advancements, and supply chain reliability are paramount. This evolution suggests that companies that prioritize these aspects will likely emerge as leaders in the glioblastoma multiforme market.

## Recent News & Developments

Recent developments in the India Glioblastoma Multiforme Market have been noteworthy, particularly regarding advancements in treatments and initiatives by key pharmaceutical companies. AstraZeneca and Roche continue to enhance their portfolios with innovative therapies aimed at tackling this aggressive form of brain cancer. In September 2023, Merck and Co. announced promising results from their latest clinical trials, potentially expanding their presence in the Indian market. Growth in the market valuation of companies like Amgen and Bayer is significantly impacting the landscape, reflecting an increasing focus on Research and Development for novel drugs.

Moreover, in July 2023, Celgene secured a strategic partnership with local firms to bolster its chemotherapy options, which indicates a growing trend towards collaboration in the Indian healthcare sector. The market is projected to see a compound annual growth rate of approximately 8% over the next few years, driven by rising incidence rates and advancements in medical technology.

Historical events, such as Bristol Myers Squibb's introduction of a new treatment regimen in March 2022, further illuminate the dynamics within the India Glioblastoma Multiforme Market, along with increasing government initiatives to improve cancer care and patient access to innovative therapies in the country.

## Report Scope

| MARKET SIZE 2024 | 147.05(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 159.58(USD Million) |
| MARKET SIZE 2035 | 361.54(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.52% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Bristol-Myers Squibb (US), Merck & Co (US), Roche (CH), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Pfizer (US), Bayer (DE) |
| Segments Covered | Treatment Type, End User Type |
| Key Market Opportunities | Advancements in targeted therapies and immunotherapies present growth opportunities in the glioblastoma multiforme market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition in the glioblastoma multiforme market. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What was the market valuation of glioblastoma multiforme in India in 2024?**
A: The market valuation of glioblastoma multiforme in India was $147.05 Million in 2024.

**Q: What is the projected market valuation for glioblastoma multiforme in India by 2035?**
A: The projected market valuation for glioblastoma multiforme in India is $361.54 Million by 2035.

**Q: What is the expected CAGR for the glioblastoma multiforme market in India during the forecast period 2025 - 2035?**
A: The expected CAGR for the glioblastoma multiforme market in India during the forecast period 2025 - 2035 is 8.52%.

**Q: Which treatment type had the highest valuation in the glioblastoma multiforme market in 2024?**
A: Chemotherapy had the highest valuation in the glioblastoma multiforme market, with a range of $40.0 Million to $100.0 Million in 2024.

**Q: What are the key players in the glioblastoma multiforme market in India?**
A: Key players in the glioblastoma multiforme market include Bristol-Myers Squibb, Merck & Co, Roche, Novartis, Eli Lilly and Company, Amgen, AstraZeneca, Pfizer, and Bayer.

**Q: What was the valuation range for surgery in the glioblastoma multiforme market in 2024?**
A: The valuation range for surgery in the glioblastoma multiforme market was $30.0 Million to $75.0 Million in 2024.

**Q: How does the valuation of radiation therapy compare to that of immunotherapy in 2024?**
A: In 2024, radiation therapy had a valuation range of $25.0 Million to $60.0 Million, whereas immunotherapy ranged from $20.0 Million to $50.0 Million.

**Q: What is the projected growth trend for ambulatory surgical centers in the glioblastoma multiforme market?**
A: Ambulatory surgical centers are projected to grow, with a valuation range of $40.0 Million to $90.0 Million in 2024.

**Q: What segment had the lowest valuation in the glioblastoma multiforme market in 2024?**
A: The segment 'Tumor Treating Field (TTF) Therapy' had the lowest valuation in the glioblastoma multiforme market, ranging from $15.0 Million to $40.0 Million in 2024.

**Q: What is the expected trend for the 'Others' segment in the glioblastoma multiforme market by 2035?**
A: The 'Others' segment is expected to grow, with a projected valuation range of $37.05 Million to $101.54 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-glioblastoma-multiforme-market-52253*